GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » EBITDA Margin %

Akeso (HKSE:09926) EBITDA Margin % : -11.16% (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Akeso EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Akeso's EBITDA for the six months ended in Jun. 2024 was HK$-123 Mil. Akeso's Revenue for the six months ended in Jun. 2024 was HK$1,103 Mil. Therefore, Akeso's EBITDA margin for the quarter that ended in Jun. 2024 was -11.16%.


Akeso EBITDA Margin % Historical Data

The historical data trend for Akeso's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso EBITDA Margin % Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial -457.43 - -527.21 -151.99 47.99

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -385.92 -95.41 70.59 -49.81 -11.16

Competitive Comparison of Akeso's EBITDA Margin %

For the Biotechnology subindustry, Akeso's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akeso's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Akeso's EBITDA Margin % falls into.



Akeso EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Akeso's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=2375.994/4950.72
=47.99 %

Akeso's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-123.105/1103.181
=-11.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akeso  (HKSE:09926) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Akeso EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Akeso's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Akeso Business Description

Traded in Other Exchanges
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.
Executives
Xia Yu 2501 Other
Wang Zhongmin Maxwell 2501 Other
Li Baiyong 2501 Other
Green Court Capital Holdings Limited 2201 Interest of corporation controlled by you
Green Court Capital Management Limited 2102 Investment manager
Green Court Management Holdings Llc 2201 Interest of corporation controlled by you
Yao Yulin 2201 Interest of corporation controlled by you
Shenzhen Capital Group Co., Ltd. 2201 Interest of corporation controlled by you
Xia Yu 2501 Other
Shen Zhen Shi Chuang Xin Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Zheng Xun
Zhong Shan Shi Xun Xiang Gu Quan Tou Zi Guan Li Qi Ye You Xian He Huo
Cantrust (far East) Limited 2301 Trustee
Aquae Hyperion Limited 2101 Beneficial owner
Htkf Investments Limited 2101 Beneficial owner

Akeso Headlines

No Headlines